Oramed Pharmaceuticals Inc. — Form 10-K Summary
Reporting period: Fiscal year ended August 31, 2013; filed November 26, 2013. The request labels this “2013 Q4,” but the filing reports full-year results, not standalone fourth-quarter results. Oramed is a development-stage pharmaceutical company focused on oral delivery of insulin and other proteins. It reported no product revenue.
Key financial results
| Metric | FY 2013 | FY 2012 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | No product revenue |
| Research and development, net | $2.272 million | $1.681 million | Up 35% |
| General and administrative | $2.032 million | $1.203 million | Up 69% |
| Net loss | $4.232 million | $3.344 million | Loss increased 27% |
| Basic and diluted loss per share | $0.59 | $0.57 | Loss per share increased |
| Cash used in operating activities | $3.395 million | $2.302 million | Use increased |
With no revenue, operating or profit margins are not meaningful. R&D growth reflected clinical-trial activity and higher share-based compensation; G&A growth included higher share-based compensation, legal and consulting costs, in part related to the Nasdaq listing.
Financial position and liquidity
- At August 31, 2013, cash and cash equivalents were $2.272 million, short-term bank deposits were $5.247 million, and marketable securities were $0.956 million. The securities were D.N.A. Biomedical shares and were subject to market-price and trading-volume risk.
- Current assets were $8.644 million, current liabilities $0.498 million, and working capital $8.146 million. Total assets were $8.660 million; stockholders’ equity was $8.131 million.
- The balance sheet showed no warrant liability at year-end (versus $0.637 million in 2012) and no conventional borrowings were reported. Current liabilities consisted principally of payables and accrued expenses.
- Operating activities used $3.395 million; investing activities used $4.570 million, primarily for short-term deposits; and financing activities provided $5.824 million. Cash and cash equivalents fell by $2.159 million, mainly as funds were moved into short-term deposits.
- Oramed raised approximately $20.860 million net from equity financing cumulatively through August 31, 2013; FY 2013 financing included a July registered offering with approximately $4.239 million in net proceeds. The company estimated $5.737 million of spending for the 12 months beginning September 1, 2013, including $4.203 million of net R&D costs.
Business developments and changes
- Oral insulin candidate ORMD0801 remained in early clinical development. Following FDA feedback on its IND application, the company began a 30-person Phase 2a sub-study in July 2013 before proceeding to the planned Phase 2b study.
- The company began a clinical trial of oral exenatide in January 2013 and a human trial of combined oral insulin and exenatide in February 2013. The filing describes combination-treatment results in pigs as encouraging, not as proof of human efficacy.
- Three patents were issued during FY 2013; the company reported eight issued patents and 30 pending patent applications.
- Oramed’s common stock began trading on Nasdaq in February 2013. It completed a $4.239 million-net registered direct offering in July and issued shares for services. Outstanding warrants and options totaled approximately 2.344 million at year-end, creating potential dilution.
Outlook, risks, and unusual items
- Management expected to fund planned development for at least 12 months based on available resources and commitments, while acknowledging that additional financing might be needed. It was evaluating financing alternatives and expected to seek equity financing and grants.
- The filing gives conflicting timing for the Phase 2b trial: the Business section says expected to begin in the third quarter of calendar 2014, while MD&A says the second quarter. The filing text does not provide a consistent expected start date.
- Principal risks include clinical-trial failure or delay, regulatory non-approval, the need for substantial additional capital, lack of product revenue, dependence on third-party suppliers and future commercial partners, intellectual-property challenges, competition, and operating exposure in Israel.
- FY 2013 included a $296,982 expense associated with amending and exchanging certain investor warrants, after which the warrants were no longer classified as liabilities. The company also reported a $205,062 income-tax benefit, primarily related to the expiration of the statute of limitations for a subsidiary tax year.
- Oramed reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls and internal control over financial reporting. The independent auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Confirm the FDA’s requirements and actual progress of the Phase 2a sub-study, and resolve the filing’s conflicting Phase 2b start-date disclosures.
- Verify current cash, deposits, marketable securities, spending rate, and financing needs against the filing’s $5.737 million planned expenditure estimate.
- Review subsequent clinical-trial results, safety and efficacy data, and regulatory communications; the filing’s early-stage results do not establish product approval or commercial viability.
- Assess dilution from outstanding options and warrants, future equity financing, and the terms and status of material investor rights.
- Check the value, liquidity, and subsequent sales of the D.N.A. Biomedical investment, as well as the conditions attached to Israeli government grants.